The research group's extensive cell-type-specific dataset suggests that, albeit statistically insignificant, CD4+ T-cells tended to have a higher migratory capacity compared to CD8+ T-cells from fingolimod-untreated MS patients; however, significant reduction in T-cell migration in the presence of fingolimod was observed. Here, CD8A is linked to myeloid sarcoma.